A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Cancer Biology Bookmark and Share

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology

Cancer Biology

City of Hope's Department of Cancer Biology offers a multidisciplinary research and training environment in a number of scientific areas, including:
 
  • Biomedical Informatics
  • Cancer Metabolism
  • Cancer Prevention and Diagnosis
  • Developmental Biology
  • Drug Resistance
  • Epigenetics
  • Hormonal Carcinogenesis
  • Genetics
  • Genomics
  • Tumor Biology

 

The department focuses on understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair and epigenetics as they relate to the development and progression of cancer. Researchers within the department collaborate with clinical and basic research programs within City of Hope and with other research centers nationally and internationally. The research team explores mechanisms of cancer development (known as carcinogenesis) and aim to develop powerful approaches to cancer prevention and to improve diagnostic tools for detecting cancer early, when it is most treatable.


Laboratory Research

Shiuan Chen, Ph.D. – Chair and Professor - Hormones and Cancer: Chemoprevention
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
 
WenYong Chen, Ph.D.Associate Professor - Epigenetics, Cancer and Aging
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
 
Gerald Holmquist, Ph.D. - Professor Emeritus
 
Jeremy Jones, Ph.D. Assistant Professor - Translational research in Urologic Oncology
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
 
Susan Kane, Ph.D.   – Professor Emeritus - Drug Resistance
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about the mechanism of action why treatments fail and which patients will best respond to specific therapies.
 
Mei Kong, Ph.D. – Assistant Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
 
Edward Newman, Ph.D. – Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
 
Timothy O'Connor, Ph.D. – Associate Chair and Professor - DNA repair, mutagenesis and cancer
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
 
Arthur Riggs, Ph.D. – Adjunct Professor (Chairperson-Diabetes and Director Emeritus, Beckman Research Institute) - DNA Methylation and Mammalian Gene Regulation
Dr. Riggs' lab research is broad-based and encompasses chromatin structure-function and gene regulation. Current studies include epigenetic changes in early mouse development, including demethylation mechanisms.
 
Judith Singer-Sam, Ph.D. – Professor Emeritus - Epigenetics and Developmental Biology
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
 
Timothy W. Synold, Pharm. D.Professor;  Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold has been actively investigating the pharmacokinetics and pharmacodynamics of anticancer agents for nearly 25 years. His current research is focused on the blood-brain-brain barrier and its impact on drug delivery to the CNS. Dr. Synold also participates in many of the drug development efforts of City of Hope Cancer Center members, and is Director of the Analytical Pharmacology Core Facility and the Clinical Immunobiology Correlative Studies Laboratory.
 
S. Emily Wang, Ph.D. – Associate Professor - Growth Factors and Cancer
Dr. Wang's group focuses on the role of signaling by growth factor receptors and oncogenes in cancer progression as well as the development of molecular therapeutics based on mechanistic study.
 

Cancer Biology Faculty

Cancer Biology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • The outlook and length of survival has not changed much in the past 25 years for patients suffering from an aggressive form of pancreatic cancer known as pancreatic ductal adenocarcinoma (PDAC). These patients still have few options for therapy; currently available therapies are generally toxic and do not incre...
  • “With bladder cancer, the majority of patients that I see can be cured,” said urologist Kevin Chan, M.D., head of reconstructive urology at City of Hope. “The challenge is to get patients the same quality of life that they had before surgery.” To meet this challenge, Chan and the urologic team at City of Hope [...
  • Already pioneers in the use of immunotherapy, City of Hope researchers are now testing the bold approach to cancer treatment against one of medicine’s biggest challenges: brain cancer. This month, they will launch a clinical trial using patients’ own modified T cells to fight advanced brain tumors. One of but a...
  • Brain cancer may be one of the most-frightening diagnoses people can receive, striking at the very center of who we are as individuals. Further, it often develops over time, causing no symptoms until it’s already advanced. Listen to City of Hope Radio as Behnam Badie, M.D., director of the Brain Tumor Pro...
  • The whole is greater than the sum of its parts. It takes a village. No man is an island. Choose your aphorism: It’s a simple truth that collaboration usually is better than isolation. That’s especially true when you’re trying to introduce healthful habits and deliver health care to people at risk of disease and...
  • When Maryland Governor Larry Hogan announced earlier this week that he has the most common form of non-Hodgkin lymphoma, he was giving voice to the experience of more than 71,000 Americans each year. The announcement came with Hogan’s promise to stay in office while undergoing aggressive treatment for the...
  • The spine can be affected by many different kinds of tumors. Malignant, or cancerous, tumors can arise within the spine itself. Secondary spinal tumors, which are actually much more common, begin as cancers in another part of the body, such as the breast and prostate, and then spread, or metastasize, to the spi...
  • Although most cancer occurs in older adults, the bulk of cancer research doesn’t focus on this vulnerable and fast-growing population. City of Hope and its Cancer and Aging Research Team aim to change that, and they’re getting a significant boost from Professional Practice Leader Peggy Burhenn, R.N....
  • Liz Graef-Larcher’s first brain tumor was discovered by accident six years ago. The then-48-year-old with a long history of sinus problems and headaches had been sent for an MRI, and the scan found a lesion in her brain called a meningioma – a tumor that arises in the meninges, the layers of tissue that cover a...
  • The colon and rectum are parts of the body’s gastrointestinal system, also called the digestive tract. After food is digested in the stomach and nutrients are absorbed in the small intestine, the remaining material moves down into the lower large intestine (colon) where water and nutrients are absorbed. The low...
  • If there is one truism about hospital stays it is that patients want to get out. For many, however, the joy of being discharged is tempered by the unexpected challenges that recovery in a new setting may pose. Even with professional help, the quality of care and treatment that patients receive at City of Hope [...
  • Jana Portnow, M.D., associate director of the Brain Tumor Program at City of Hope, didn’t expect to specialize in treating brain tumors. But, early in her career, she undertook a year of research on pain management and palliative care and, in that program, got to know many patients with brain tumors. After that...
  • Ask any patient: Nurses are as pivotal in their care as doctors. They answer the call of a patient in the middle of the night, they hold the patient’s hand as he or she takes on yet another round of treatment and, in the best-case scenario, they wave goodbye as the patient leaves the hospital, […]
  • Many oncologists, not to mention their patients, might think that there’s no place for mathematical analysis in the treatment of cancer. They might think that all treatment decisions are based on unique factors affecting individual patients, with no connection to other patients and their treatment regimen...
  • Within three days in 2007, Stephanie Hosford, then 37, learned that she was pregnant with her long-awaited second child – and that she had triple-negative breast cancer. Soon afterward, Hosford discovered that she and her husband, Grant, had been approved to adopt a little girl from China.  After encountering m...